Overexpression of hsa_circ_0001445 reverses oxLDL‑induced inhibition of HUVEC proliferation via SRSF1

hsa_circ_0001445 的过度表达可通过 SRSF1 逆转 oxLDL 诱导的 HUVEC 增殖抑制

阅读:9
作者:Guiying Liang, Sihua Chen, Sha Xin, Liang Dong

Abstract

Atherosclerosis is a primary cause of multiple types of cardiovascular disease, including myocardial infarction. In addition, injury of human umbilical vein endothelial cells (HUVECs) can lead to the development of atherosclerosis. Circular (circ)RNAs participate in atherosclerosis. It has previously been shown that circRNA cSMARCA5 (hsa_circ_0001445) expression is downregulated in atherosclerosis. However, the effects of hsa_circ_0001445 on the proliferation of HUVECs remain unclear. In order to mimic atherosclerosis in vitro, HUVECs were treated with oxidized low‑density lipoprotein (oxLDL). The expression levels of specific genes and proteins were detected in HUVECs by reverse transcription‑quantitative PCR and western blot analysis, respectively. Cell proliferation was assessed by Cell Counting Kit‑8 and 5‑Ethynyl‑2'‑deoxyuridine staining. Cell apoptosis and 5,5',6,6'‑Tetrachloro‑1,1',3,3'‑tetraethyl‑imidacarbocyanine staining were examined by flow cytometry. In addition, the association between hsa_circ_0001445 and serine/arginine‑rich splicing factor 1 (SRSF1) was investigated by RNA pull‑down assay. hsa_circ_0001445 expression was downregulated in oxLDL‑treated HUVECs. Moreover, oxLDL‑induced inhibition of HUVEC proliferation was significantly reversed by overexpression of hsa_circ_0001445. oxLDL notably inhibited tube formation and mitochondrial membrane potential in HUVECs, while these effects were markedly reversed by hsa_circ_0001445 overexpression. Furthermore, overexpression of hsa_circ_0001445 reversed oxLDL‑induced activation of β‑catenin by binding to SRSF1. Collectively, these data demonstrated that overexpression of hsa_circ_0001445 reversed oxLDL‑induced inhibition of HUVEC proliferation via activation of the SRSF1/β‑catenin axis. These findings may provide novel targets for the treatment of atherosclerosis.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。